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ABSTRACT 
Background: Chronic rhinosinusitis (CRS) is a prevalent and disruptive disease. Medical 
management including nasal steroid sprays is the primary treatment modality. Computational 
fluid dynamics (CFD) has been used to characterize sinonasal airflow and intranasal drug 
delivery; however, variation in simulation methods indicates a need for large scale CFD model 
validation.  
     Methods: Anatomic reconstructions of pre and post-operative CT scans of 3 functional 
endoscopic sinus surgery patients were created in Mimics(TM). Fluid analysis and drug particle 
deposition modeling were conducted using CFD methods with Fluent(TM) in 18 cases. Models 
were 3D printed and in vitro studies were performed using Tc99-labeled Nasacort(TM). Gamma 
scintigraphy signals and CFD-modeled spray mass were post-processed in a superimposed grid 
and compared. Statistical analysis using overlap coefficients (OCs) evaluated similarities 
between computational and experimental distributions and Kendall’s tau rank correlation 
coefficient was employed to test independence.  
     Results: OCs revealed strong agreement in percent deposition and grid profiles between 
CFD models and experimental results (mean [range] for sagittal, axial, and coronal grids were 
0.69 [0.57], 0.61 [0.49], and 0.78 [0.44], respectively). Kendall’s tau values showed strong 
agreement (average 0.73) between distributions, which were statistically significant (p < 0.05) 
apart from a single coronal grid in one model and two sagittal grids of another. 
     Conclusions: CFD modeling demonstrates statistical agreement with in vitro experimental 
results. This validation study is one of the largest of its kind and supports the applicability of 
CFD in accurately modeling nasal spray drug delivery and using computational methods to 
investigate means of improving clinical drug delivery. 
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Introduction: 
Chronic rhinosinusitis (CRS) is an inflammatory condition characterized by the cardinal 
symptoms of: nasal congestion, nasal drainage, facial pain and pressure, and decreased smell 
persisting for longer than 12 weeks1. It is a profoundly prevalent disease, affecting 
approximately 12% of the US population and an estimated 5-12% worldwide2,3. This results in 
similarly heavy financial and emotional burdens on both an individual and population level. 
Annual spending for CRS in the US was projected to be up to $10.8 billion dollars by 2020 and 
is still increasing4. Indirect costs considering loss of productivity and psychologic burden are 
even higher, with self-reported perceptions of health (measured by health utility scores) by CRS 
patients comparable to patients with Parkinson’s disease and end stage renal disease with 
dialysis dependence2.  
The treatment of CRS is largely medical. In addition to nasal saline irrigation, nasal 
corticosteroid sprays are the gold standard of initial management and function to modulate the 
underlying inflammatory mediators of disease1. Despite widespread use, approximately 50% of 
patients fail appropriate medical treatment5,6. This is attributed in part to the limited penetration 
of medication within the sinonasal passage, a limitation which persists even after surgical 
intervention7,8. Several factors have been identified in contributing to suboptimal deposition at 
target sites, including: nozzle position, inhalation characteristics, and particle size9-13. 
 In an effort to improve drug delivery and thus outcomes to medical management, 
increasing study has focused on characterizing the location and amount of drug delivery 
achieved using current administration methods. Computational fluid dynamics (CFD) has arisen 
in recent decades as an effective tool for modeling sinonasal airflow and its role in intranasal 
drug delivery10,11,14,15. In addition to overcoming the logistical and ethical burdens of measuring 
drug delivery in vivo, CFD modeling offers the immediate ability to measure the effect of an 
alteration in medication administration, such as particle size or position of delivery device, in a 
way that lends itself well to optimizing medical intervention.  
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A number of previous studies have implemented CFD to characterize sinonasal airflow 
and intranasal drug delivery10,14-18. Since all CFD studies are subject to a number of simplifying 
assumptions, validation of CFD results is necessary19. The validation studies that have been 
performed comparing in vitro with in silico modeling are largely limited by their relatively small 
scale, often isolated to a single anatomical model, and by the broad manner in which drug 
deposition location is characterized20,21. Deposition location is predominantly described in either 
large subunits (anterior/middle/posterior compartments) or by percent penetration past a 
particular anatomic landmark (i.e. internal nasal valve), limiting the statistical comparison 
between in vitro and in silico models8,9,20,21. A recent CFD investigation of deposition increases 
achieved by aiming a nasal sprayer toward specific nasal target sites in 3 subjects with CRS 
used gamma scintigraphy in both nasal sides of one 3D-printed model to confirm simulated 
spray mass22.  The study presented here expands on this work to provide the largest scale 
validation of its kind to date, using overlap coefficients to compare CFD modeling and 
experimental results in 18 distinct cases with varying sets of spray use conditions and pre vs 
post-surgical changes. This work supports the use of CFD methods to explore and quantify 
nasal drug delivery improvements. 
Materials and Methods: 
Computational model creation: 
To generate the models for CFD analysis, anatomic reconstructions were made of de-
identified CT scans previously obtained as part of an ongoing study protocol and approved by 
the institutional review board (IRB) at the University of North Carolina at Chapel Hill. Pre- and 
post-operative CT scans were obtained for 3 functional endoscopic sinus surgery (FESS) 
patients (Table 1).  
Anatomical reconstructions were created in MimicsTM 18.0 imaging software (Materialise, 
Inc., Plymouth, MI, US) with initial Hounsfield units (HU) thresholding values from -1024 to -300 
(Siemens) and -1024 to 300 or 400 (cone-beam CT, CBCT) used to designate the airspace of 
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the sinonasal passages and paranasal sinuses. Reconstructed airspaces were then hand-edited 
for accuracy and reviewed on a case-by-case basis by a clinical rhinologist. These models were 
then imported into ICEM-CFDTM 15.0 (ANSYS, Inc., Canonsburg, PA, US) as previously 
described15,23. Inlet and outlet boundary surfaces were designated at the nostril inlets and 
nasopharynx, respectively. For analytical comparison purposes with the experimental results, a 
3D grid was designed in ICEMTM and superimposed on the model based on designated 
reference points (Figure 1). Grids comprised planes in the coronal (xy), sagittal (yz), and axial 
(xz) orientations and were designed to match the grid designation created in the experimental 
analysis, described below. 
Tetrahedral meshes of at least 3.8 million cells with quality > 0.3 were also created in 
ICEMTM, in a manner described in previous work16. Three 0.1-mm-thick prism layers were then 
added and the final, hybrid meshes were smoothed globally until the number of elements in the 
0 – 0.1 quality range was smaller than 0.0005%.  
Fluid modeling and drug deposition:  
Meshes were then exported to FluentTM for modeling of airflow and drug particle 
deposition. Flow parameters assumed laminar nasal airflow, as supported by previous 
findings24-26. To mimic the gentle inspiration directed by nasal spray use instructions, steady 
inspiratory airflow simulations were carried out at twice the resting minute volume using 
methods described previously23,27. Resting breathing minute volume for each patient was 
measured pre-operatively using LifeShirt plethysmography (range 9 to 12 L/min)28. In the 
simulations, gauge pressure was set at 0 at the nostrils with a negative pressure set at the 
nasopharynx sufficient to generate the patient-specific flow rate (range -7.4 to -18.9 Pa). 
FluentTM provides numerical solutions for flow characteristics by solving the differential 
equations governing conservation of mass and momentum for laminar, incompressible flow as 
described in detail in previous work23,27. Acceptable convergence was determined by small 
residuals and stabilization of outlet mass flow rate.  
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Following fluid analysis, drug particle deposition was determined through Fluent’sTM 
Discrete Phase Model (DPM) with Langrangian particle tracking performed by integrating the 
particle transport equation of the Runge-Kutta method20. Initial parameters were defined in such 
a way as to introduce droplet particles into the system in a manner consistent with nasal spray 
actuation. These parameters were based on studies of particle size and plume geometry of 
Triamcinolone acetonide (NasacortTM) nasal sprays performed by Next Breath, LLC as 
described previously, resulting in a volume-based droplet size distribution with a Dv50 of 43.81 
µm and GSD of 1.994 µm and cone half angle of 27.93°.22 Spray velocity was set to 18.5 m/s.29 
Drug particle size distribution was characterized using the formula described by Cheng et al30. 
As our validation study was concerned with comparing fractional deposition location rather than 
absolute amount of drug delivery, this size distribution was scaled to a 1mg total delivered 
amount to reduce the number of particles and alleviate the time burden of CFD modeling. 
Sprays were simulated as release from a point at the tip of the virtual nozzle in either the left or 
right nasal vestibule. As the presence of the nozzle has been previously shown to be largely 
negligible, it was not included within the 3D space of the model23.  
Airflow was solved for each of the 6 anatomical models (pre- and post-operative for the 3 
patients, models labeled “PRE” and “POST”, respectively). As each model provided distinct left 
and right-hand sides (labeled “LHS” and “RHS”), there were a total of 12 regions of interest. 
Additionally, nasal drug delivery was simulated with the nozzle in two different positions: 
“current use” (CU), consistent with provided medication instructions, or by “line of sight” (LOS), 
in which the nozzle was optimally orientated toward the ostiomeatal complex22. Although outside 
the scope of this validation study, evaluating LOS as a manner of improving nasal drug delivery 
is a topic of ongoing interest22. This set of conditions, sides, and models resulted in the potential 
for 24 distinct trials for comparison purposes. This was reduced to a total of 18 due to 
anatomical constraints (certain models lacked a clear “line of sight”) and a lack of experimental 
data for the right-hand side of model SD02.  
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Experimental design:  
As described in previous work, a 3D printer was used to print the pre- and post-surgical 
models for the three study subjects23. The anterior portion of the model comprising the external 
nares and anterior vestibules was printed from a flexible component which was fitted on to the 
posterior portion of the model, which was printed from a rigid Watershed material (DSM Somos, 
Elgin, Illinois). This allowed for easy removal of the anterior portion of the model to isolate the 
signal depositing within the regions of interest deeper within the sinonasal passages. Aiming 
devices were also 3D printed to interface with the medication nozzle and the external nare to 
ensure consistency in nozzle position with CFD modeling and between individual experimental 
trials. Experimental set-up is the same as that established in previous work by this group22 
(Figure 2).  
To measure amounts and location of drug deposition experimentally, a small solution of 
99mTechnetium as sodium pertechnetate, Na[99mTcO4] was added to the medication for a 
single actuation of no more than 10 μCi of activity as in published methods31,32. A steady 
inspiratory flow of air was drawn through the replica to simulate gentle inspiration on a patient-
specific basis27,31. A filter was placed to collect any particles that traveled to the nasopharyngeal 
outlet and a tissue used to retrieve any residual deposited spray dripping from the external nose 
to be included in the total signal measurement. Medication was hand actuated a single time into 
one nostril in either current use (CU) or line of sight (LOS) orientations. A medium resolution 
large field of view gamma camera (Body Scan, MiE America, Inc., Elk Grove Village, IL) was 
used to measure 99mTc gamma activity associated with the deposition pattern for the mass of 
labeled spray within the model. Resolution of the gamma scans was determined by pixel size, 
with one pixel corresponding to 2.38mm for a 256 x 256 matrix scan. Using this unit of 
measurement, a grid system was created to assign gamma activity of drug deposition to 
compartments for comparison purposes (Figure 3). Grid lines were spaced 4 pixels (9.52mm) 
apart in sagittal and axial orientations. Given the predominant spray deposition at the medial 
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aspect of the model, grid lines were spaced closer together at the midline of the model in the 
frontal view to provide increased specificity (range from 2.38 – 14.28mm). 
Post-processing: 
Solved particle trajectories in FluentTM provided Cartesian coordinates of individual 
particle deposition locations that were collected in Microsoft® Excel. Data was post-processed 
to exclude points landing within the anterior portion of the nose. Particles were assigned to grid 
compartments by location and associated masses were summed to determine total deposited 
dose per each compartment. Since CFD modeling was performed using a scaled down spray of 
representative particle mass distribution, as described above, mass amounts were converted to 
percent mass in order to perform statistical comparison with experimental results.  
Despite matching grids to pre-defined reference points (americium markers) and using 
the established grid spacing, the virtual grid in ICEMTM did not exactly match that applied to the 
experimental model. There were several sources identified in contributing to this effect, the first 
being that the experimental grid was limited by the resolution of the gamma-scintigraphy 
camera, with smallest discrete pixel sizes measuring 2.38mm. The dimensions of the physical 
model and americium marker spacing were not designed in units of pixel size and thus did not 
fall along exact increments. Due to the nature of gamma-scintigraphy signal capturing and 
image processing, grid positioning was performed manually, with small shifts made to maximize 
americium signals within identified marker locations. This was further complicated by the effect 
of visual perspective and foreshortening in captured images that was absent from the 
computational models. To allow for this reasonable variation in grid positioning, a “grid shift” was 
applied to the virtual grid system, in which each orthogonal set of planes was linearly translated 
1 pixel distance (2.38mm) in each direction. The original plane positions are heretofore referred 
to as “reference planes” with the shifted planes designated as “positive shift” and “negative shift” 
based on direction of translation along the corresponding axes (Figure 4). 
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Statistical analysis:  
Statistical analysis was performed using overlap coefficients (OCs) to evaluate 
similarities between computational and experimental distributions. This measures the proportion 
of overlap between the two deposition distributions. Values range between 0 and 1, with a value 
of 0 indicating no overlap and a value of 1 representing a perfect match. This was performed 
separately for distributions in each orthogonal set of planes, as represented by the equation: 
𝑂𝐶 = 1 −  
∑ |𝑠𝑖𝑚𝑖 − 𝑒𝑥𝑝𝑖|
𝑛
𝑖=1
2
 
where n is the number of grid compartments along each corresponding axis, simi represents the 
proportion of simulation deposition in the ith grid compartment along the axis, and expi is the 
corresponding experimental deposition in that grid compartment. 
In addition, the Kendall’s tau rank correlation coefficient and the p-value for the Kendall’s 
tau test for independence were obtained. The p-values for the test for independence were false 
discovery rate corrected using the Benjamini-Hochberg procedure. The correction was based on 
all 18 models for all three directions and the reference, negative, and positive grid positions. 
Results: 
For each model, fractional mass deposition was post-processed into grid compartments 
along each axis for both computational and experimental data. Analysis was limited to 
deposition within the posterior rigid portion of the model (excluding the external nose and 
anterior vestibule) in the anatomical region of interest. In CFD models, a single simulated spray 
actuation resulted in percent depositions ranging from 2.07% for Model SD04PRE-LHS-CU to 
63.63% for Model SD05PRE-RHS-LOS with a mean percent deposition of 27.99%. The percent 
deposition in experimental trials ranged from 16.43% for Model SD05POST-RHS-CU to 57.66% 
for Model SD02POST-LHS-LOS with a mean of 34.74%. Due to the inherent dependence 
between grid compartments, with particle masses falling into one compartment or another, 
graphs were generated to more easily depict general trends in mass deposition location within 
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each model. A representative sample is shown below (Figure 5) illustrating percent mass 
deposition within computational and experimental compartments for Model SD05PRE-LHS-
LOS. The computational results include the reference grids as well as the positive and negative 
shifts. Experimental results are represented by mean value across multiple trials with associated 
error bars.   
In order to compare the computational and experimental data to evaluate the accuracy 
of CFD modeling it was necessary to analyze overall distribution among grid compartments. 
This was performed using overlap coefficients (OCs), which are provided for each model by grid 
system in Tables 2-4. Mean OCs were highest in coronal plane compartments, followed by 
sagittal and then axial distributions.  
The OCs among coronal plane compartments were highest in the reference grid position 
(mean 0.78) compared to negative and positive shifts (0.77 and 0.73, respectively). The highest 
OCs for sagittal and axial planes were achieved with the positively-shifted plane positions; 
however the reference position never provided the worst agreement. For sagittal planes, mean 
OCs in descending order were 0.78 (positive shift), 0.69 (reference planes), and 0.51 (negative 
shift). For axial planes mean OCs were 0.63 (positive shift), 0.61 (reference planes), and 0.54 
(negative shift).   
Also provided in these tables are the associated Kendall’s tau rank correlation 
coefficients, which were used to assess independence between computational and 
experimental data, with their representative p-values. Mean Kendall’s tau values of distributions 
in reference plane positions were 0.66 (coronal), 0.76 (sagittal), and 0.76 (axial). P-values were 
all significant (p ≤ 0.05) apart from two sets of sagittal grids for one model (SD04POST-RHS-
CU) and one shifted coronal grid for another (SD05PRE-RHS-LOS).  
Discussion: 
The results of this study reveal strong agreement in percent deposition and grid profiles 
between CFD models and experimental results as measured by OCs. This method of validation 
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is novel in the statistical methods of rank correlation as well as the independent evaluation of 
drug deposition along each axis and the use of small geometric compartments rather than large 
subunits for comparison purposes. Although limited in direct anatomic correlates, reporting 
mass deposition by grid compartments is still effective in demonstrating depth of particle 
penetration within the sinonasal passages and better serves the underlying objective of 
providing numerous, uniform bins for increased sensitivity in statistical analysis.  
There were certain physical limitations inherent in the experimental model. The foremost 
among these was the relatively large pixel size resulting from the resolution of the gamma 
scintigraphy images and the difficulty in creating a uniform grid to accurately overlie model 
geometries that were not designed with this unit of measurement in mind. Although shifting the 
best-estimate reference grids was performed to evaluate the most accurate grid position, this 
effect hinders perfect concordance between the constructed systems of comparison. The 
consistently improved OC values for the positively-shifted sagittal and axial planes suggests a 
possible underlying skew in the manual adjustments performed in superimposing the grid over 
the gamma scintigraphy results, a source of error that may be minimized in the future by 
designing model reference points with these considerations in mind. Multiple experimental trials 
were performed for each model and set of spray conditions; however, this was limited by the 
time-intensive nature of radiotracer use in a given model. Another potential source of variation 
among experimental trials was the hand actuation of the nasal spray. Although a dedicated 
aimer was implemented to provide consistency in positioning, hand actuation was performed by 
different individuals with unavoidable variations in applied pressure and performance. Few 
cases, especially those with low amounts of particle deposition, demonstrated a marked 
increase in fractional experimental deposition relative to computational results. This is perhaps 
due to the beneficial effect of mechanical stenting of the nasal valve resulting from nozzle 
deformation in the anterior nose. These cases still demonstrated strong overlap coefficients, 
signifying overall agreement between drug deposition distributions. 
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Limitations in CFD modeling arise from certain assumptions applied in simplifying the 
simulation. These include releasing spray particles from the nozzle at a single point source as 
well as having particles instantly assume the volume distribution pattern measured 
experimentally at a distance 3cm from the nozzle tip. Models could further be refined by 
considering the effects of humidity within the sinonasal passages and the corresponding 
alterations in particle behavior and volume.  
In using OCs to evaluate the correlation between dependent bins, there is an additional 
degree of concordance not necessarily represented numerically. This derives from the fact that 
compartment bins that had discrepancies in amounts of overlap between CFD and experimental 
models were often located adjacent to one another. This is more easily appreciated graphically, 
as illustrated in Figure 6. This reflects similarity in the overall profile of mass distributions, rather 
than discrepancies arising from compartments in anatomically unrelated locations. 
Mean OCs were highest in coronal plane compartments, representing best overall 
agreement in modeling drug deposition in an anterior to posterior direction. This further supports 
the clinical strength of this modeling system, as this distribution represents the depth of 
penetrance of drug particles past the internal nasal valve into the sinonasal passage and has 
been the focus of much of the existing work in CFD modeling of intranasal drug delivery22,32. 
The additional use of Kendall’s rank correlation coefficients provided a less robust, but 
additionally useful measure of independence between computational and experimental results. 
Although these values supported independence for the vast majority of models, this was not 
proven for the sagittal compartments in the reference and negative shift positions for Model 
SD04POST-RHS-CU. This is attributed to the fact that in this axis the positively shifted grid is 
demonstrated to provide a better correlation and is likely the most accurate grid position. 
Similarly, the negatively shifted coronal grid in SD05PRE-RHS-LOS demonstrated a lack of 
significance, but the reference plane position resulted in a strong OC and Kendall’s tau value 
suggesting a more accurate fit in this case.  
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Although mean fractional deposition in the posterior part of the model was similar 
between CFD and experimental models (27.99% and 34.74%, respectively), these values reveal 
that the majority of medication is deposited in the anterior portion of the nose, a limitation that 
has been established in the literature and largely attributed to the obstructive nature of the 
internal nasal valve9,30,31,33. Although outside the direct scope of this validation study, this trend 
is easily identified in the collected data. While previous CFD studies have found negligible 
effects from modeling space occupied by a spray nozzle in the nostril, the effects of possible 
mechanical alterations to the internal nasal framework have not been examined23. With the 
establishment of CFD as an effective tool for evaluating nasal drug delivery, it is hoped that the 
factors contributing to this overall poor drug delivery may be identified and remedied.  
Conclusion: 
The described method of CFD modeling demonstrates statistical agreement with in vitro 
experimental results. This validation study is one of the largest of its kind and supports the 
applicability of CFD in accurately modeling nasal spray drug delivery. Computational models 
facilitate investigations into methods of improving clinical drug delivery without the associated 
financial, physical, and time burdens of physical experimentation. Future work is ongoing in 
determining exactly which methods of spray administration are successful in achieving optimal 
drug delivery and the additional effects of surgical intervention on improving such delivery. 
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TABLES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 – Study subject demographics and performed surgical procedures. FESS here refers to 
comprehensive surgery of the maxillary, ethmoid, sphenoid, and frontal sinuses. 
  
Subject Patient Characteristics Surgical Procedures 
SD02 
70-year old 
Male, 67.5kg 
Caucasian 
Bilateral FESS 
SD04 
24-year old 
Female, 93.1kg 
Caucasian 
Septoplasty 
Bilateral maxillary antrostomy, 
Bilateral anterior ethmoidectomy, 
Bilateral inferior turbinate resection 
SD05 
41-year old 
Male, 88kg 
Caucasian 
Septoplasty 
Bilateral FESS 
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CORONAL PLANES Overlap Coefficients (OCs) Kendall’s tau values p-values 
Model Neg Ref Pos Neg Ref Pos Neg Ref Pos 
SD02POST-LHS-CU 0.84 0.6 0.59 0.77 0.75 0.75 0.00 0.00 0.00 
SD02POST-LHS-LOS 0.81 0.83 0.82 0.77 0.8 0.77 0.00 0.00 0.00 
SD02PRE-LHS-CU 0.87 0.78 0.71 0.80 0.75 0.75 0.00 0.00 0.00 
SD02PRE-LHS-LOS 0.78 0.85 0.85 0.78 0.81 0.80 0.00 0.00 0.00 
SD04POST-LHS-CU 0.81 0.64 0.56 0.69 0.64 0.69 0.00 0.00 0.00 
SD04POST-LHS-LOS 0.73 0.74 0.69 0.67 0.69 0.69 0.00 0.00 0.00 
SD04POST-RHS-CU 0.43 0.47 0.51 0.43 0.51 0.59 0.04 0.02 0.01 
SD04PRE-LHS-CU 0.61 0.72 0.57 0.46 0.51 0.59 0.03 0.02 0.01 
SD04PRE-LHS-LOS 0.9 0.83 0.74 0.64 0.61 0.61 0.00 0.00 0.00 
SD04PRE-RHS-CU 0.89 0.79 0.72 0.67 0.64 0.79 0.00 0.00 0.00 
SD04PRE-RHS-LOS 0.72 0.86 0.86 0.61 0.56 0.64 0.00 0.01 0.00 
SD05POST-LHS-CU 0.86 0.9 0.75 0.70 0.75 0.69 0.00 0.00 0.00 
SD05POST-LHS-LOS 0.7 0.75 0.8 0.55 0.66 0.72 0.02 0.00 0.00 
SD05POST-RHS-CU 0.72 0.82 0.69 0.45 0.5 0.50 0.05 0.02 0.02 
SD05PRE-LHS-CU 0.75 0.89 0.82 0.55 0.66 0.63 0.02 0.00 0.01 
SD05PRE-LHS-LOS 0.81 0.91 0.86 0.64 0.78 0.72 0.00 0.00 0.00 
SD05PRE-RHS-CU 0.71 0.82 0.81 0.61 0.55 0.47 0.01 0.02 0.03 
SD05PRE-RHS-LOS 0.85 0.83 0.83 0.41 0.64 0.72 0.06 0.00 0.00 
Mean 0.77 0.78 0.73 0.62 0.66 0.67    
 
Table 2 – Coronal planes. Overlap coefficients and Kendall’s tau rank correlation coefficients 
with associated p-values demonstrating level of statistical agreement between mass deposition 
distributions analyzed by coronal (XY) planes 
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SAGITTAL PLANES Overlap Coefficients (OCs) Kendall’s tau values p-values 
Model Neg Ref Pos Neg Ref Pos Neg Ref Pos 
SD02POST-LHS-CU 0.5 0.82 0.75 0.73 0.66 0.58 0.00 0.00 0.01 
SD02POST-LHS-LOS 0.67 0.72 0.84 0.80 0.77 0.77 0.00 0.00 0.00 
SD02PRE-LHS-CU 0.38 0.73 0.76 0.69 0.77 0.77 0.00 0.00 0.00 
SD02PRE-LHS-LOS 0.7 0.84 0.8 0.80 0.80 0.75 0.00 0.00 0.00 
SD04POST-LHS-CU 0.64 0.77 0.95 0.80 0.85 0.88 0.00 0.00 0.00 
SD04POST-LHS-LOS 0.58 0.73 0.84 0.74 0.85 0.77 0.00 0.00 0.00 
SD04POST-RHS-CU 0.25 0.27 0.56 0.19 0.27 0.43 0.39 0.21 0.05 
SD04PRE-LHS-CU 0.47 0.82 0.92 0.73 0.77 0.70 0.00 0.00 0.00 
SD04PRE-LHS-LOS 0.44 0.61 0.74 0.76 0.79 0.76 0.00 0.00 0.00 
SD04PRE-RHS-CU 0.27 0.51 0.92 0.56 0.67 0.73 0.01 0.00 0.00 
SD04PRE-RHS-LOS 0.45 0.66 0.91 0.73 0.78 0.77 0.00 0.00 0.00 
SD05POST-LHS-CU 0.19 0.7 0.83 0.65 0.87 0.82 0.02 0.00 0.00 
SD05POST-LHS-LOS 0.56 0.83 0.73 0.78 0.87 0.82 0.00 0.00 0.00 
SD05POST-RHS-CU 0.84 0.81 0.77 0.76 0.65 0.76 0.01 0.02 0.01 
SD05PRE-LHS-CU 0.32 0.79 0.66 0.65 0.85 0.85 0.02 0.00 0.00 
SD05PRE-LHS-LOS 0.8 0.7 0.65 0.85 0.91 0.73 0.00 0.00 0.01 
SD05PRE-RHS-CU 0.55 0.55 0.74 0.78 0.78 0.73 0.01 0.01 0.01 
SD05PRE-RHS-LOS 0.53 0.57 0.7 0.61 0.78 0.84 0.03 0.01 0.00 
Mean 0.51 0.69 0.78 0.70 0.76 0.75    
 
Table 3 – Sagittal planes. Overlap coefficients and Kendall’s tau rank correlation coefficients 
with associated p-values demonstrating level of statistical agreement between mass deposition 
distributions analyzed by sagittal (YZ) planes 
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AXIAL PLANES Overlap Coefficients (OCs) Kendall’s tau values p-values 
Model Neg Ref Pos Neg Ref Pos Neg Ref Pos 
SD02POST-LHS-CU 0.53 0.53 0.54 0.79 0.81 0.85 0.00 0.00 0.00 
SD02POST-LHS-LOS 0.41 0.5 0.54 0.63 0.67 0.75 0.00 0.00 0.00 
SD02PRE-LHS-CU 0.23 0.37 0.43 0.60 0.63 0.69 0.01 0.00 0.00 
SD02PRE-LHS-LOS 0.26 0.33 0.44 0.69 0.69 0.71 0.00 0.00 0.00 
SD04POST-LHS-CU 0.56 0.6 0.63 0.76 0.83 0.83 0.00 0.00 0.00 
SD04POST-LHS-LOS 0.36 0.42 0.49 0.70 0.76 0.79 0.00 0.00 0.00 
SD04POST-RHS-CU 0.64 0.64 0.62 0.76 0.76 0.79 0.00 0.00 0.00 
SD04PRE-LHS-CU 0.59 0.66 0.75 0.69 0.64 0.74 0.00 0.01 0.00 
SD04PRE-LHS-LOS 0.46 0.54 0.62 0.76 0.78 0.74 0.00 0.00 0.00 
SD04PRE-RHS-CU 0.56 0.68 0.67 0.79 0.86 0.89 0.00 0.00 0.00 
SD04PRE-RHS-LOS 0.7 0.82 0.79 0.82 0.89 0.84 0.00 0.00 0.00 
SD05POST-LHS-CU 0.67 0.76 0.73 0.84 0.76 0.76 0.00 0.00 0.00 
SD05POST-LHS-LOS 0.51 0.56 0.61 0.67 0.70 0.70 0.00 0.00 0.00 
SD05POST-RHS-CU 0.68 0.59 0.52 0.78 0.81 0.72 0.00 0.00 0.00 
SD05PRE-LHS-CU 0.6 0.74 0.67 0.85 0.85 0.86 0.00 0.00 0.00 
SD05PRE-LHS-LOS 0.69 0.76 0.81 0.79 0.79 0.85 0.00 0.00 0.00 
SD05PRE-RHS-CU 0.65 0.72 0.67 0.72 0.72 0.72 0.00 0.00 0.00 
SD05PRE-RHS-LOS 0.67 0.73 0.75 0.76 0.79 0.78 0.00 0.00 0.00 
Mean 0.54 0.61 0.63 0.74 0.76 0.78    
 
Table 4 – Axial planes. Overlap coefficients and Kendall’s tau rank correlation coefficients with 
associated p-values demonstrating level of statistical agreement between mass deposition 
distributions analyzed by axial (XZ) planes 
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FIGURES/LEGENDS 
 
Figure 1 – Grid Creation. Illustrated here is the SD05-PRE (pre-surgical) CFD model with the 
three orthogonal grid systems designated by columns (C1-12) in the xy (coronal) plane, 
columns (C1-9) in the yz (sagittal) plane, and rows (R1-12) in the zx (axial) plane. 
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Figure 2 – Experimental set-up. Components of experimental set-up are shown in expanded 
view here for clarity. For each model, NasacortTM bottle was consistently positioned within the 
soft portion of the nose using the 3D-printed aiming device. Anterior and posterior portions of 
the model were printed to fit with snap-on interface. (From Basu et al. (submitted). Used with 
permission.)22 
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Figure 3 (a) Superimposed grid framework overlying the 3D-printed model of SD05-PRE. (b) 
Grid superimposed over gamma scintigraphy results in a sagittal view. Smaller boxes mark the 
positions of americium reference markers. (c) Grid superimposed over gamma scintigraphy 
results in a frontal view.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a)                (b)          (c) 
 9.52mm                                                            9.52mm   14.28mm    2.38mm 
              7.14mm 
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Figure 4 – Grid Shifts. Reference planes were positioned in closest match to the experimental 
grid system based on the most anteriorly-located americium marker. Reference planes were 
then shifted by 1 pixel (2.38mm) in the negative and positive direction along the corresponding 
axis to achieve negative and positive grid shifts, and to account for variation in experimental grid 
positioning. (From Basu et al. (submitted). Used with permission.)22 
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Figure 5 – Fractional mass deposition by grid compartment for Model SD05PRE-LHS-LOS. 
Inset within each graph is the representative grid system previously illustrated in Figure 1. 
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Figure 6 – Overlap coefficients displayed graphically. Figure 7a depicts the strong overlap 
coefficient (0.91) for Model SD05PRE-LHS-LOS in the reference coronal grid position. Here the 
computational deposition amounts are depicted in blue and the experimental values in red. The 
experimental values overlay the simulation so that any overlap is represented as red. The blue 
portions thus characterize a lack of overlap. Figure 7b depicts the less strong overlap coefficient 
(0.50) for Model SD02POST-LHS-CU in the negative sagittal grid position. Although there is 
less agreement between computational and experimental results, the discrepancy occurs in 
adjacent compartments, maintaining the overall shape of the mass distribution. 
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